Erasca, Inc. Cash and Restricted Cash
Erasca, Inc. (ERAS) had Cash and Restricted Cash of $42.95 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-11
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $42.95M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $47.66M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $74.21M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $70.64M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $42.95M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $47.66M 10-Q · filed 2026-05-11 | |
| 2025-12-31 | $74.21M 10-K · filed 2026-03-12 | |
| 2025-09-30 | $70.64M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $66.55M 10-Q · filed 2026-08-11 | |
| 2025-03-31 | $70.89M 10-Q · filed 2026-05-11 | |
| 2024-12-31 | $68.15M 10-K · filed 2026-03-12 | |
| 2024-09-30 | $69.29M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $173.21M 10-Q · filed 2024-08-12 | |
| 2024-03-31 | $173.21M 10-Q · filed 2025-08-12 | $77.13M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $93.48M 10-K · filed 2025-03-20 | |
| 2023-09-30 | $113.27M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $139.19M 10-Q · filed 2024-08-12 | |
| 2023-03-31 | $273.16M 10-Q · filed 2024-05-08 | |
| 2022-12-31 | $284.63M 10-K · filed 2024-03-27 | |
| 2022-09-30 | $219.67M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $219.67M 10-Q · filed 2023-11-09 | $298.42M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $333.75M 10-Q · filed 2023-05-15 | |
| 2021-12-31 | $360.89M 10-K · filed 2023-03-23 | |
| 2021-09-30 | $446.22M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $156.80M 10-Q · filed 2022-08-11 | |
| 2021-03-31 | $170.40M 10-Q · filed 2022-05-12 | |
| 2020-12-31 | $65.69M 10-K · filed 2022-03-24 | |
| 2020-09-30 | $62.33M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $104.34M 10-Q · filed 2021-08-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |